AgomAb Therapeutics NV
AGMB
34 hedge funds and large institutions have $337M invested in AgomAb Therapeutics NV in 2026 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 7 closing their positions.
37% more capital invested
Capital invested by funds: $245M → $337M (+$91.7M)
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
6% more funds holding
Funds holding: 32 → 34 (+2)
4.78% more ownership
Funds ownership: 47.92% → 52.7% (+4.8%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$29M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.14M |
| 3 |
O
OrbiMed
New York
|
+$2.17M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$1.57M |
| 5 |
AA
ALPS Advisors
Denver,
Colorado
|
+$563K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
-$3.15M |
| 2 |
SGM
Seven Grand Managers
Bronxville,
New York
|
-$1.72M |
| 3 |
Millennium Management
New York
|
-$999K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$787K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$525K |
AGMB Hedge Fund Activity: Q2 2026 in Review
34 of the 8,211 institutional investors tracked by Wall St. Rank reported a position in AgomAb Therapeutics NV (AGMB) for Q2 2026, worth a combined $337M — up 37% from $245M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new AGMB positions and 7 closed out — a net gain of 2 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Redmile Group, adding an estimated $29M. The largest seller was LMR Partners, exiting entirely with an estimated $3.15M sold.
- 34 institutional investors held AgomAb Therapeutics NV (AGMB) as of Q2 2026, up from 32 in Q1 2026.
- Funds reported $337M of AgomAb Therapeutics NV stock for Q2 2026, up 37% quarter-over-quarter.
- 9 funds opened new AgomAb Therapeutics NV positions in Q2 2026 and 7 closed out, a net change of +2 holders.
- The largest AgomAb Therapeutics NV buyer in Q2 2026 was Redmile Group, an estimated $29M added.
- The largest AgomAb Therapeutics NV seller in Q2 2026 was LMR Partners, an estimated $3.15M sold.
Based on aggregated 13F filings for Q2 2026.